Premature discontinuation of any oral anticoagulant, including apixaban, increases thrombotic event risk. This is not due to any rebound effect from discontinuation. To reduce this risk, administering another anticoagulant is advised.<ref name="urlELIQUIS® (apixaban) tablets Factor Xa Inhibitor">{{cite web |url = http://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm333723.pdf |title = ELIQUIS® (apixaban) tablets Factor Xa Inhibitor |date = August 2014 |publisher= FDA | accessdate= 2014-11-02}}</ref>

 

